<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Title</title>
</head>
<body>
<table cellpadding="0" cellspacing="0" width="100%" bgcolor="#b7b7b7" class="m_6232911469480614299fullWidth"><tbody><tr><td align="center">
    <div align="center" style="display:inline-block;width:850px;max-width:850px;background-color:#e0e2e1" class="m_6232911469480614299mailContainer">

        <div style="width:850px" class="m_6232911469480614299fullWidth">
            <table cellpadding="0" cellspacing="0" width="850" bgcolor="#e9e9e9" class="m_6232911469480614299fullWidth">
                <tbody><tr>
                    <td width="270" class="m_6232911469480614299hideMobile">

                    </td>
                    <td align="center" class="m_6232911469480614299topTD">
                        <img src="https://ci3.googleusercontent.com/proxy/-M-T0aGXg2afsq4oPbF6sz_DDgIM4yIknRh3uG2MqR3rjXxEy62HkoBDIu63n3IE1y00WJorXI7Y6hfmVDu5OLIIdsfxIJXhkS-NYhPC0XCjY7Ka=s0-d-e1-ft#http://www.combustion.co.uk/clients/onexila/images/logoTop.jpg" class="m_6232911469480614299logoTop CToWUd">
                    </td>
                    <td width="270" align="center" valign="middle" class="m_6232911469480614299topTD m_6232911469480614299topTD2">
                        <br><a href="http://www.onexila.co.uk" style="color:rgba(0,0,0,0);text-decoration:underline" target="_blank" data-saferedirecturl="https://www.google.com/url?hl=en&amp;q=http://www.onexila.co.uk&amp;source=gmail&amp;ust=1493354321960000&amp;usg=AFQjCNH8yhx2uhk3FdYSXxSLT48U27CNaw">
                        <span style="font-family:'OpenSans',Arial!important;color:#909190;font-size:14px;line-height:10px;text-decoration:none">view in browser</span>
                    </a>
                    </td>
                </tr>
                </tbody></table>
        </div>

        <div style="width:850px;background-color:#e0e2e1" class="m_6232911469480614299fullWidth">
            <table cellpadding="0" cellspacing="0" bgcolor="#e0e2e1" class="m_6232911469480614299fullWidth">
                <tbody>
                <tr>
                    <td width="70" style="width:70px!important" class="m_6232911469480614299hideMobile"><img src="https://ci5.googleusercontent.com/proxy/xiwdlY4namAU10EvAzzbz8Nd1B62JpfNlVGctnocpceKuDzWuKJYH4LoaztB0P764gRe2RW95FU-Lg_cO50h5F7MEnMtImTyR91SsTSfhun3ObJrVVKKuTGKsQ=s0-d-e1-ft#http://www.combustion.co.uk/clients/onexila/images/spacerMainLeft.jpg" style="display:block" class="CToWUd"></td>
                    <td align="left" valign="bottom" width="406" style="width:406px" class="m_6232911469480614299tdMain">
                        <span style="font-family:'OpenSansL',Arial!important;color:#333333;font-size:37px;line-height:42px" class="m_6232911469480614299title1">He could fall</span><br>
                        <span style="font-family:'ArchivoBlack',Arial!important;color:#0ec2e7;font-size:37px;line-height:42px" class="m_6232911469480614299title2"><strong>prey to his aid</strong></span><br><br>
                        <span style="font-family:'OpenSans',Arial!important;color:#909190;font-size:13px" class="m_6232911469480614299para1">We will be at stand 14 at the British Pain Society <br>
				50th anniversary ASM. Visit us to find out more<br>
				about Onexila<sup>™</sup>XL</span>
                        <br><br><br>
                        <a class="m_6232911469480614299btnTellMeMore" href="http://www.onexila.co.uk" style="display:inline-block;padding-left:40px;padding-right:40px;padding-top:10px;padding-bottom:10px;text-align:center;border:2px solid #0ec2e7;border-radius:6px!important;font-family:'OpenSansB',Arial!important;color:#0ec2e7;font-size:16px;line-height:16px;text-decoration:none" target="_blank" data-saferedirecturl="https://www.google.com/url?hl=en&amp;q=http://www.onexila.co.uk&amp;source=gmail&amp;ust=1493354321960000&amp;usg=AFQjCNH8yhx2uhk3FdYSXxSLT48U27CNaw">
                            Tell me more
                        </a>
                        <br><br><br><br>
                        <p style="font-family:'OpenSansL',Arial!important;color:#848484;font-size:11px;line-height:16px" class="m_6232911469480614299para2">
                            Onexila<sup>TM</sup> XL is licensed for severe pain, which can be adequately managed only
                            with opioid analgesics. OnexilaTM XL is indicated in adults, and adolescents aged
                            12 years and older.
                        </p><br>
                    </td>
                    <td class="m_6232911469480614299imgTop" width="372" style="width:373px!important;max-width:373px!important;max-height:563px!important;overflow:hidden!important;font-size:0px;display:inline-block" valign="bottom"><img src="https://ci3.googleusercontent.com/proxy/HGdOjjUYL7vBhB-MN1T-S7HLkJ7NrAfp5xYhz9_4E-tsztyjbl6mYgOtnxeSiqkQDGh-TOfSE6Zu5Cp9Vp80VNJdUYBL7ejeRh_AyQMO78_gu4bR=s0-d-e1-ft#http://www.combustion.co.uk/clients/onexila/images/imgMain.jpg" style="display:block!important;vertical-align:top!important" class="CToWUd a6T" tabindex="0"><div class="a6S" dir="ltr" style="opacity: 0.01; left: 1051.5px; top: 832.594px;"><div id=":1yl" class="T-I J-J5-Ji aQv T-I-ax7 L3 a5q" role="button" tabindex="0" aria-label="Download attachment " data-tooltip-class="a1V" data-tooltip="Download"><div class="aSK J-J5-Ji aYr"></div></div></div></td>
                </tr>
                </tbody>
            </table>
        </div>

        <div style="width:850px" class="m_6232911469480614299fullWidth">
            <table cellpadding="0" cellspacing="0" width="850" class="m_6232911469480614299fullWidth">
                <tbody><tr>
                    <td class="m_6232911469480614299col m_6232911469480614299circleBox" width="50%" align="center" valign="top" bgcolor="#e9e9e9" style="height:290px;font-family:'OpenSans',Arial!important;color:#0ec2e7;font-size:17px;line-height:28px">
                        <br>
                        <img src="https://ci5.googleusercontent.com/proxy/NlRnaVUHuKfznWhd1CbHGuXk3X2RhZ3E1Ya3H6wyWjG3Ki5fMAi0tRSGZJIAO-7-DXgbTJNpNCATnozvA0ny_qMlge214dGMIE8X8irQaaAWEiYJ=s0-d-e1-ft#http://www.combustion.co.uk/clients/onexila/images/circle1.jpg" class="CToWUd"><br><br>
                        Approximately 40% of the UK<br>
                        population suffers from a form of<br>
                        severe or chronic pain.<sup>1</sup> Severe pain<br>
                        has a marked impact on quality of life,<br>
                        and a person's ability to undertake<br>
                        everyday activities.<sup>2</sup>
                        <br><br>
                    </td>
                    <td class="m_6232911469480614299col m_6232911469480614299circleBox" align="center" bgcolor="#0ec2e7" valign="top" style="font-family:'OpenSansB',Arial!important;color:#ffffff;font-size:17px;line-height:28px">
                        <br>
                        <img src="https://ci6.googleusercontent.com/proxy/hEGQTDuj8-7ulotXBzcAuDCrSjD7bNKFswfxtwls39jZ2dEEm49uAmQyOzTK9Nr-EYq-6jHQcempBZdY3doaGvZ4tiIY6NXCoAVkAYW_IKQOwr4_=s0-d-e1-ft#http://www.combustion.co.uk/clients/onexila/images/circle2.jpg" class="CToWUd"><br><br>
                        Onexila<sup>TM</sup> XL once-daily oxycodone<br>
                        is a new treatment option for<br>
                        patients with severe pain, offering<br>
                        comparable efficacy and safety to<br>
                        twice-daily oxycodone,<sup>3</sup> with no<br>
                        price premium vs Longtec<sup>©</sup>.<sup>4</sup>
                        <br><br>
                    </td>
                </tr>
                </tbody></table>
        </div>

        <table cellpadding="0" cellspacing="0" width="850" class="m_6232911469480614299fullWidth">
            <tbody><tr>
                <td align="center" bgcolor="#001149" style="font-family:'OpenSans',Arial!important;color:#ffffff;font-size:20px;line-height:32px" class="m_6232911469480614299findOutMore m_6232911469480614299removeBR">
                    <br><br>
                    OnexilaTM<sup>XL</sup> also has pharmacokinetic properties that may<br>
                    help control the risk of dependence and addiction associated<br>
                    with prolonged use of opioid analgesics, along with physical<br>
                    properties that confront the expected methods of abuse.<sup>5,6</sup>
                    <br><br><br>
                    <table cellpadding="0" cellspacing="0" width="322" class="m_6232911469480614299tableFindOutMore"><tbody><tr><td style="border:2px solid #fff;height:90px" align="center">
                        <a href="http://www.onexila.co.uk" style="font-family:'OpenSansSB',Arial!important;color:#fffff0;font-size:20px;line-height:26px;text-decoration:none" target="_blank" data-saferedirecturl="https://www.google.com/url?hl=en&amp;q=http://www.onexila.co.uk&amp;source=gmail&amp;ust=1493354321960000&amp;usg=AFQjCNH8yhx2uhk3FdYSXxSLT48U27CNaw">
                            Find out more at<br>onexila.co.uk
                        </a>
                    </td></tr></tbody></table>
                    <br><br>
                    <p style="font-family:'OpenSans',Arial!important;color:#ffffff;font-size:10px;line-height:18px">
                        1. Fayaz A et al. (2016) <em>BMJ Open</em> 6:e010364. 2. Breivik H et al. (2013) <em>BMC Public Health</em>, 13:1229. 3. Lux EA et al. (2014) <em>Curr Med Res Op</em> 30,<br>
                        2365-2375. 4. MIMS. Longtec® pricing. Available at: <a href="http://www.mims.co.uk/drugs/pain/pain-fever/longtec" style="text-decoration:none;color:#fffff0" target="_blank" data-saferedirecturl="https://www.google.com/url?hl=en&amp;q=http://www.mims.co.uk/drugs/pain/pain-fever/longtec&amp;source=gmail&amp;ust=1493354321960000&amp;usg=AFQjCNFP9iwde4UWZpJEhlMHfBdzBjm3TQ">http://www.mims.co.uk/drugs/<wbr>pain/pain-fever/longtec</a>. [Accessed April 2017]. 5. Data<br>
                        206 v 1.0 March 2017
                    </p><br><br>

                </td>
            </tr>
            </tbody></table>

        <table cellpadding="0" cellspacing="0" width="850" bgcolor="#ebebeb" class="m_6232911469480614299fullWidth"><tbody><tr><td class="m_6232911469480614299legal">
            <br><br>
            <table cellpadding="0" cellspacing="0" width="850" class="m_6232911469480614299fullWidth" style="text-align:justify">
                <tbody><tr>
                    <td class="m_6232911469480614299hideMobile"><img src="https://ci5.googleusercontent.com/proxy/sqE22llY0RmxqnUyrCvZL9yWW7IR0ARU1DkrsiN2gk1LZzq3Dbihr8ftjeA65WuJVbdK3V8jgf6Qp6XDYVyd5wKCvZzGrD1mcnkrdnDN_1hanl7X3wiBfpg=s0-d-e1-ft#http://www.combustion.co.uk/clients/onexila/images/spacerFooter.jpg" class="CToWUd"></td>
                    <td class="m_6232911469480614299col2 m_6232911469480614299info" width="393" align="left" style="width:393px;max-width:393px!important;font-family:'OpenSans',Arial!important;color:#808080;font-size:10px;line-height:14px;text-align:justify;text-justify:inter-word">
                        <strong>Onexila XL (oxycodone hydrochloride) Prolonged-release Tablets Prescribing Information
                            (please refer to the full SmPC before prescribing)</strong><br><br>
                        Indications: Onexila XL is indicated for severe pain, which can be adequately managed only with opioid analgesics in adults, and adolescents aged 12 years and older. Available strengths: Onexila XL 10, 20, 40 and 80mg x 28 tablets. Dosage and method of use: Dosage depends on the pain intensity and patient's individual susceptibility to the treatment. In general, the initial dose for opioid naÃ¯ve patients is 10 mg given once daily. Patients already receiving opioids may start treatment with higher dosages taking into account their experience with former opioid therapies. Because of individual differences in sensitivity for different opioids, it is recommended that patients should start conservatively with Onexila XL after conversion from other opioids, with 50-75% of the calculated oxycodone dose. Some patients who take Onexila XL need rapid release analgesics as rescue medication to control breakthrough pain during dose adjustment. Onexila XL is not indicated for the treatment of
                        acute pain and/or breakthrough pain. The single dose of the rescue medication should amount to 1/6 of the equianalgesic daily dose of Onexila XL. Use of the rescue medication more than twice daily indicates that the dose of Onexila XL needs to be increased. In general, the lowest effective analgesic dose of Onexila XL should be chosen. For treatment of non-malignant pain a daily dose of 40mg is generally sufficient. Patients with cancer-related pain may require dosages of 80-120mg. If higher doses are required, the dose should be decided individually balancing efficacy with tolerance and risk of undesirable effects. Onexila should not be taken longer than necessary. If long-term treatment is necessary careful and regular monitoring is required to determine whether and to what extent treatment should be continued. If therapy with oxycodone is no longer required, it may be advisable to reduce the daily dose gradually in order to prevent symptoms of a withdrawal syndrome. Risk patients
                        , for example patients with impaired renal or hepatic function, low body weight or slow metabolism of medicinal products, should initially receive half the recommended adult dose if they are opioid naÃ¯ve. For the lower starting dose, other medicinal products with more appropriate strengths are available. Onexila XL should be taken once daily at the dosage determined, with or independent of meals with a sufficient amount of liquid. Onexila XL must be swallowed whole, not chewed or crushed. Contraindications: Onexila XL is contraindicated in patients with a hypersensitivity to the active substance or to any of the excipients, severe respiratory depression with hypoxia and /or hypercapnia, severe chronic obstructive pulmonary disease, Cor pulmonale, severe bronchial asthma, paralytic ileus and acute abdomen, delayed gastric emptying. Special warnings and precautions for use: Onexila XL should be used with caution in elderly or debilitated patients, patients with severe impairment of l
                        ung, hepatic or renal function, myxoedema, hypothyroidism, Addison's disease, intoxication psychosis, prostatic hypertrophy, alcoholism, known opioid dependence, delirium tremens, pancreatitis, diseases of the biliary tract, biliary or ureteric colic, conditions with increased brain pressure, disturbances of circulatory regulation, epilepsy or seizure tendency and patients taking MAO inhibitors. Oxycodone should be used with caution in patients
                    </td>
                    <td class="m_6232911469480614299hideMobile"><img src="https://ci5.googleusercontent.com/proxy/sqE22llY0RmxqnUyrCvZL9yWW7IR0ARU1DkrsiN2gk1LZzq3Dbihr8ftjeA65WuJVbdK3V8jgf6Qp6XDYVyd5wKCvZzGrD1mcnkrdnDN_1hanl7X3wiBfpg=s0-d-e1-ft#http://www.combustion.co.uk/clients/onexila/images/spacerFooter.jpg" class="CToWUd"></td>
                    <td class="m_6232911469480614299col2" width="393" align="left" valign="top" style="width:393px;max-width:393px!important;font-family:'OpenSans',Arial!important;color:#808080;font-size:10px;line-height:14px;text-align:justify;text-justify:inter-word">
                        undergoing bowel-surgery, and only administered post-operatively when the bowel function has been restored. The safety of Onexila XL used pre-operatively has not been established and cannot be recommended. Long-term use of oxycodone can cause the development of tolerance. Chronic use of oxycodone can cause physical dependence. Withdrawal symptoms may occur following abrupt discontinuation of therapy. Oxycodone has a primary dependence potential.  Onexila XL should be prescribed with special care in patients with a history of alcohol and drug abuse. The administration of chewed or crushed tablets leads to rapid release and absorption of a potentially fatal dose of oxycodone. Patients with severe hepatic impairment should be closely monitored. Athletes should be made aware this medicine may cause a positive reaction to'anti-doping' tests. This medicinal product contains sucrose, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or
                        sucrase-isomaltase insufficiency should not take this medicine. Interactions: Strong CYP2D6 inhibitors may have an effect on the elimination of oxycodone; potential interactions should be taken into account. Concomitant use of Onexila XL with alcohol should be avoided. Pregnancy and lactation: Use of this medicinal product should be avoided in patients who are pregnant or lactating. Infants born to mothers who have received opioids during the last 3-4 weeks before giving birth should be monitored for respiratory depression. Ability to drive and use machines: Oxycodone can impair alertness and reactivity to such an extent that the ability to drive and operate machinery is affected or ceases altogether. The treating physician must assess the individual situation as to whether the patient can drive and/or operate machinery. Undesirable effects: For the full list of side effects consult the SmPC for Onexila XL.'Very Common' and'Common' and selected'Serious' adverse reacti
                        ons are included in this prescribing information. Very common (≤1/10) adverse reactions include somnolence, dizziness, headache, constipation, nausea, vomiting and pruritus. Common (≤1/100 to &lt;1/10) adverse reactions include anorexia, various psychological adverse reactions including changes in mood, changes in activity and changes in cognitive performance, paraesthesia, lowering of blood pressure, rarely accompanied by secondary symptoms such as palpitations, syncope, respiratory depression, bronchospasm, dry mouth rarely accompanied by thirst and difficulty swallowing, gastrointestinal disorders such as abdominal pain, diarrhoea, eructation, dyspepsia, skin eruptions including rash, in rare cases increased photosensitivity, in isolated cases urticaria or exfoliative dermatitis, micturition disturbances, asthenia, hyperhidrosis and chills. Uncommon (≤1/1,000 to &lt;1/100) serious adverse reactions include hypersensitivity and syndrome of inappropriate antidi
                        uretic hormon
                        e secretion. Rare serious (≤1/10000 to &lt;1/1000) adverse reactions include seizures, ileus and cellulitis. Very rare serious &lt;1/10000) adverse reactions include anaphylactic reactions. MA number: PL 33155/0042, 0044-0046 Cost: Per packs of 28: £12.52 for 10mg and 20mg; £25.04 for 40mg; and £50.09 for 80mg. MAH: Rivopharm UK Ltd, 30th Floor, 40 Bank Street, Canary Wharf, London, E14 5NR. Distributor: Aspire Pharma Ltd, Unit 4, Rotherbrook Court, Bedford Road, Petersfield, Hampshire, GU32 3QG. Legal category: POM Schedule 2 Controlled Drug. Date reviewed: March 2017. Version number: 1010356189 v 2.0.
                    </td>
                    <td class="m_6232911469480614299hideMobile"><img src="https://ci5.googleusercontent.com/proxy/sqE22llY0RmxqnUyrCvZL9yWW7IR0ARU1DkrsiN2gk1LZzq3Dbihr8ftjeA65WuJVbdK3V8jgf6Qp6XDYVyd5wKCvZzGrD1mcnkrdnDN_1hanl7X3wiBfpg=s0-d-e1-ft#http://www.combustion.co.uk/clients/onexila/images/spacerFooter.jpg" class="CToWUd"></td>
                </tr>
                </tbody></table>

            <table cellpadding="0" cellspacing="0" class="m_6232911469480614299fullWidth m_6232911469480614299footer">
                <tbody><tr><td width="180" align="right">
                    <a href="http://www.onexila.co.uk" style="font-family:'OpenSans',Arial!important;color:#0cc3e5;text-decoration:none;font-size:15px" target="_blank" data-saferedirecturl="https://www.google.com/url?hl=en&amp;q=http://www.onexila.co.uk&amp;source=gmail&amp;ust=1493354321961000&amp;usg=AFQjCNE8aWh-dgvaejUlkLCyTTVNVf2Cmw">Unsubscribe</a>
                </td><td width="160" align="center">
                    <img src="https://ci4.googleusercontent.com/proxy/lim0bdRTJNP8tj-xmpJ1P5GJRdYw5cCtn-vOxaq_VU1LbDSGa4bWdr2ICKvOFyGcmL225yIJaWScBTTAr5Vlfgj7w38hWZUwIbOFuD_tRbsAnOV8ACo=s0-d-e1-ft#http://www.combustion.co.uk/clients/onexila/images/foterLogo.jpg" class="CToWUd">
                </td><td class="m_6232911469480614299footerLast" align="center" style="font-family:'OpenSans',Arial!important;color:#808080;line-height:13px;font-size:11px">
                    ONX/UK/041706<br>Date of preparation: April 2017
                </td></tr></tbody></table>

        </td></tr></tbody></table>

    </div>
    <div class="m_6232911469480614299footerBR"><br><br><br><br><br><br><br><br><br><br><br><br></div>
</td></tr></tbody></table>
</body>
</html>